AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag

AstraZeneca AZN announced that the FDA has granted priority review to a supplemental biologics license application (sBLA) seeking approval for the expanded use of Enhertu (trastuzumab deruxtecan) to treat unresectable or metastati https://www.nasdaq.com/articles/astrazenecas-azn-sbla-for-enhertu-gets-fdas-priority-tag